Two Modes of Action Explains Daclatasvir’s Potency
Share
Follow Us
New Study On Hepatitis C Drug Treatment in Vivo and in Vitro
Feb. 18, 2013 — Hepatitis C virus (HCV) infection affects about 4 million in the United States and is the primary cause of liver cirrhosis and liver cancer. Current therapy against HCV is suboptimal. Daclatasvir, a direct acting antiviral (DAA) agent in development for the treatment of HCV, targets one of the HCV proteins (i.e., NS5A) and causes the fastest viral decline (within 12 hours of treatment) ever seen with anti-HCV drugs. An interdisciplinary effort by mathematical modelers, clinicians and molecular virologists has revealed that daclatasvir has two main modes of action against HCV and also yields a new, more accurate estimate of the HCV half-life.
Results of the NS5A study are published in the Proceedings of the National Academy of Sciences (PNAS) on February 18th, 2013.
Continue reading this entire article:
http://www.sciencedaily.com/releases/2013/02/130218164128.htm
